Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisa F Newcomb

Showing results (1-10 of 62) with videos related to

Pageof 7
Sort By:
Biochemical and Biophysical Research Communications|February 1, 2002
Src family kinase-dependent phosphorylation of a 29-kDa caveolin-associated proteinLisa F Newcomb, Cynthia Corley Mastick
European Urology|September 10, 2018
Reply to Runqiang Yuan's Letter to the Editor re: James T. Kearns, Anna V. Faino, Lisa F. Newcomb, et al. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. Eur Urol 2018;73:706-12James T Kearns, Lisa F Newcomb, Daniel W Lin
Biometrical Journal. Biometrische Zeitschrift|January 5, 2026
Time-Dependent Predictive Accuracy Metrics in the Context of Interval Censoring and Competing RisksZhenwei Yang, Dimitris Rizopoulos, Lisa F Newcomb, et al.
Cancer Medicine|March 16, 2024
Exploring the relation of active surveillance schedules and prostate cancer mortalityZhenwei Yang, Eveline A M Heijnsdijk, Lisa F Newcomb, et al.
Statistics in Medicine|May 26, 2025
Personalized Biopsy Schedules Using an Interval-Censored Cause-Specific Joint ModelZhenwei Yang, Dimitris Rizopoulos, Eveline A M Heijnsdijk, et al.
Urology|September 18, 2009
Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepositoryLisa F Newcomb, James D Brooks, Peter R Carroll, et al.
The Annals of Applied Statistics|January 11, 2019
ESTIMATING AND COMPARING CANCER PROGRESSION RISKS UNDER VARYING SURVEILLANCE PROTOCOLSJane M Lange, Roman Gulati, Amy S Leonardson, et al.
JAMA Oncology|December 12, 2024
Polygenic Risk Score and Upgrading in Patients With Prostate Cancer Receiving Active SurveillanceLouisa B Goss, Menghan Liu, Yingye Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2013
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance StudyDaniel W Lin, Lisa F Newcomb, Elissa C Brown, et al.
The Journal of Urology|June 18, 2011
The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional studyJesse K McKenney, Jeff Simko, Michael Bonham, et al.
Pageof 7

Showing results (1-10 of 62) with videos related to

Sort By:
Pageof 7
Biochemical and Biophysical Research Communications|February 1, 2002
Src family kinase-dependent phosphorylation of a 29-kDa caveolin-associated proteinLisa F Newcomb, Cynthia Corley Mastick
European Urology|September 10, 2018
Reply to Runqiang Yuan's Letter to the Editor re: James T. Kearns, Anna V. Faino, Lisa F. Newcomb, et al. Role of Surveillance Biopsy with No Cancer as a Prognostic Marker for Reclassification: Results from the Canary Prostate Active Surveillance Study. Eur Urol 2018;73:706-12James T Kearns, Lisa F Newcomb, Daniel W Lin
Biometrical Journal. Biometrische Zeitschrift|January 5, 2026
Time-Dependent Predictive Accuracy Metrics in the Context of Interval Censoring and Competing RisksZhenwei Yang, Dimitris Rizopoulos, Lisa F Newcomb, et al.
Cancer Medicine|March 16, 2024
Exploring the relation of active surveillance schedules and prostate cancer mortalityZhenwei Yang, Eveline A M Heijnsdijk, Lisa F Newcomb, et al.
Statistics in Medicine|May 26, 2025
Personalized Biopsy Schedules Using an Interval-Censored Cause-Specific Joint ModelZhenwei Yang, Dimitris Rizopoulos, Eveline A M Heijnsdijk, et al.
Urology|September 18, 2009
Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepositoryLisa F Newcomb, James D Brooks, Peter R Carroll, et al.
The Annals of Applied Statistics|January 11, 2019
ESTIMATING AND COMPARING CANCER PROGRESSION RISKS UNDER VARYING SURVEILLANCE PROTOCOLSJane M Lange, Roman Gulati, Amy S Leonardson, et al.
JAMA Oncology|December 12, 2024
Polygenic Risk Score and Upgrading in Patients With Prostate Cancer Receiving Active SurveillanceLouisa B Goss, Menghan Liu, Yingye Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2013
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance StudyDaniel W Lin, Lisa F Newcomb, Elissa C Brown, et al.
The Journal of Urology|June 18, 2011
The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional studyJesse K McKenney, Jeff Simko, Michael Bonham, et al.
Pageof 7